Specsavers’ renowned ‘Should’ve Gone to Specsavers’ tagline has been in-market for over 17 years. The popular colloquialism ...

The MarketWatch News Department was not involved in the creation of this content.-- Post hoc analyses include data showing investigational oral semaglutide 25 mg use was associate ...

The weekday streets are quiet in the mountain town of Caramulo, the calm broken only by the growl of a sports car or the ...

CELEBRATION, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with ...

Amgen today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved statistically significant and clinically meaningful reductions in ...

In November 2025, Iovance reported that clinical results for IOV-4001, a PD-1 inactivated TIL cell therapy, in previously treated advanced melanoma patients are anticipated in the first quarter of ...

Michael Burry’s Scion Asset Management has taken bearish positions in AI darlings Nvidia (NVDA) and Palantir (PLTR), a ...

ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers ...

New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of ...

With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help ...

New preclinical data to show anti-tumor activity of ATNM-400 in hormone-resistant and HER2-resistant breast cancer, addressing the need for new ...

Google Ads now lets one advertiser appear twice on a SERP – a change that tests fairness, transparency, and competition.